Free Virtual Workshop: Approval, Access, and Reimbursement - Can gene and cell therapies reshape the landscape?
November 10th, 14:00 GMT/9:00 ET – 60 mins
FOR PHARMA AND BIOTECH COMPANIES ONLY
As more gene and cell-based treatments seek approval, and as the approval process itself evolves, what trial design, metrics, endpoints and arguments on long-term uncertainty will companies need in order to satisfy not just regulators but payers and providers? What ongoing measures are required to grow sales post-launch?
Workshop objectives:
- Understand the key drivers and barriers in demonstrating value to payers and providers
- Share experiences in how to better leverage value to ensure successful coverage and reimbursement
Register (for free) for this Workshop now – Spaces limited ->
We will discuss:
- Key challenges that are faced by HTA/Payers? And what drives their decision making?
- Impact of landscape at launch, magnitude of response, and data quantity
- How to optimise trial design and select impactful endpoints
- Heterogeneity in gene and cell therapy solutions and the resultant impact on pricing models
Register (for free) for this Workshop now – Spaces limited ->
Your facilitator: Prof Mondher Tuomi.
Professor University of Aix-Marseille, Visiting Professor at Beijing University (Third Hospital), and CEO at Creativ-Ceutical and Director of the European Market Access University Diploma.
Prof Tuomi worked at Lundbeck A/S for over 13 years, with nearly 6 years served as Global Vice President at in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs, and competitive intelligence.
In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. Additionally, he recently created the Market Access Society to promote research and scientific activities around market access, public health and health economic assessment.
Since 2009, he also Chaired the Annual Market Access Day, a purely academic event. He is Editor in Chief of the Journal of Market Access and Health Policy (JMAHP). He has been a highly active member of ISPOR from its creation. He served as co-Chair of the Research Review Committee ISPOR Europe in 2012 and 2013. He is a recognized expert in health economics and an authority on market access and risk management. He has more than 200 scientific publications and oral communications, and has contributed to several books, the most recent “Gene and Cell Therapies: Market Access and Funding - Pharmaceuticals, Health Economics and Market Access” was published in May 2020.
Apply to attend by filling in the form on the right >>>
Take part in polls which guide the discussion and reaffirm common challenges and goals
Build word clouds, or create white boards as a group to brainstorm solutions
Break into smaller groups and deep dive in to talking points or find solutions to hypothetical cases
Apply to attend by filling in the form on the right >>>
Please let me know if you have any feedback, or if you want to get involved with the event.
Best wishes,
Izzy
Attend this free virtual workshop (pharma and biotech only)
Due to the large volume of applications, requesting to join this workshop you are not guaranteed a space.
Reuters Events Pharma will contact you as soon as possible if you are successful, with a calendar invitation and joining instructions.
Fill in your details below
Please note that the workshop organiser has their own privacy policies, and Reuters Events is not responsible for the actions or data protection practices of any organiser.
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.